Kornimate/medical-research-clean huggingface dataset:
ropivacaine concentration and rebound pain

Conditions: Radius Fracture Distal; Rebound Pain

Summary: the goal of this clinical trial is to see if the concentration of a local anesthetic (ropivacaine) in peripheral nerve block is related to the severness of pain after surgery of distal radius fractures in adults. the main questions it aims to answer are: * is concentration of ropivacaine related to severeness, duration and type of postoperative pain? * is concentration of ropivacaine related to analgetic consumption after surgery? * is concentration of ropivacaine related to block sucess rate during surgery and patient satisfaction after surgery? researchers will compare ropivacaine 3.75 mg/ml and 7.5 mg/ml used in brachial plexus peripheral nerve block. participipants are randomized to one of the two concentrations. the peripheral nerve block is standard anesthetic treatment for distal radius fractures scheduled for volar plate surgery at oslo university hospital. all other treatment for the condition will be the same as standard treatment. participants will answer a questionnaire regarding pain, physical function, medication and life quality at different points of time after surgery, up to 6 weeks after surgery.


Eligibility criteria:
inclusion criteria: * patients with distal radius fracture, scheduled for volar plate surgery * surgery up to 20 days after fracture trauma * 18 to 80 years old (inclusive) * asa 1, 2 or stable asa 3 * body mass index (bmi) 18 to 40 kg/m2 (inclusive) * weight of 50 kg or more * ability to communicate sufficiently in a scandinavian language * capable of giving a signed informed consent * ability and willingness to understand og be compliant to the study exclusion criteria: * contemporaneous painful injuries * existing long-term pain * peripheral nerve damage in the arm with radius fracture * patients who prior to fracture trauma use opioids, psycothropic drugs or medication, with or without prescription, with significantly sedative effect on regular basis. * excessive use of alcohol (more than 15 units of alchol per week for men, more than 8 units of alchol per week for women, or patients reporting to be incapable of avoiding alcohol as long as they use strong opioids). * progressive neurologic disease (inclusive diabetic neuropathy). * skin infection at the site for brachial plexus nerve block * other contraindications for brachial plexus nerve block * contraindications for ropivacaine, paracetamol, etoricoxib, dexamehtasone or oxycodone * previous allergic reaction to local anaesthetics or etoricoxib, dexamethasone, oxycodone or paracetamol. * pregnant or breast-feeding women at surgery day (they do not get excluded if they become pregnant in the follow up period after intervention and surgery)

Keywords: rebound pain peripheral nerve block distal radius fracture brachial plexus block ropivacaine
s-1-induced lacrimal drainage obstruction

Conditions: Gastric Cancer

Summary: s-1 is an effective drug in gastric cancer (gc) for palliative chemotherapy in eastern and western patients. recently, s-1 has been also reported to be an effective adjuvant therapy for gc patients who received d2 surgery in eastern asian patients. recently, the development of lacrimal drainage obstruction (ldo) caused by s-1 has been reported from some case and small-sized studies. the incidence of developing ldo has been estimated to about 15\~20% of patients receiving s-1 therapy in some retrospective studies. however, there is no prospective report on the incidence of ldo in patients receiving s-1 chemotherapy. moreover, the mechanism of developing s-1-induced ldo has not been systemically studied until now. suggested mechanism of ldo involves direct secretion of s-1 into the tear. therefore, this study was initiated to prospectively investigate the incidence of ldo in gc patients receiving adjuvant s-1 chemotherapy. in addition, the correlation between the development of ldo and the concentration of s-1 (or its metabolites) in tear and plasma will be explored. these results will help clinicians identify patients who are at high risk of developing s-1-associated ldo.


Eligibility criteria:
inclusion criteria: * patients who received curative (r0) surgery for gc * patients receiving adjuvant s-1 chemotherapy * patients with adequate major organ functions for chemotherapy * patient who have taken s-1 at least 7 days (for blood and tear sampling) exclusion criteria: * patients who are not candidate for adjuvant s-1 chemotherapy * patients with previous history of ldo * patients with other opthalmologic disease who are not appropriate to be included in this study (i.e., patients using eyedrop medication; patients with dry eye whose tears cannot be sampled)

Keywords: adjuvant chemotherapy
ultrasound-guided internal superior laryngeal nerve block for double-lumen bronchial tube

Conditions: Postoperative Sore Throat

Summary: investigate the effectiveness and safety of ultrasound-guided bilateral internal branch of the sln (isln) block for alleviating post immediately after the operation.


Eligibility criteria:
inclusion criteria: * asa 1 to 3 exclusion criteria: * patients who did not provide consent * with a pre-existing sore throat, hoarseness and upper respiratory tract infection * tracheal pathology, tracheostomy * a history of psychosis, diabetes and thyroid, oral cavity or pharynx surgery * known or suspected allergy to ropivacaine * chronic opioid use * use of nonsteroidal anti-inflammatory drug medication within 24 hours * known or suspected difficult airway * patients who will be supported by tube ventilator after the operation.
evaluate the predictive impact of the meessi score

Conditions: Emergencies; Heart Diseases

Summary: our primary purpose is to assess meessi score in predicting mortality and readmission of patients managed for acute heart failure (ahf) in emergency department. european society of cardiology recommend risk stratification for patients with ahf.

improved risk stratification of acute heart failure (ahf) in the emergency department (ed) may help physicians' decisions regarding patient admission or early discharge disposition. the meessi-ahf (multiple estimation of risk based on the emergency department spanish score in patients with ahf) score was developed to predict 30-day mortality in patients presenting with ahf eds in spain. whether it performs well in other countries is unknown. the meessi-ahf risk model includes 13 variables readily available on arrival to emergency department. the 40% of patients classified as low risk (30-day mortality: \ 2%) may clearly benefit from hospital admission. objective: to externally validate the meessi-ahf score in another country.

Eligibility criteria:
inclusion criteria: * major patient * patient admitted to emergencies with final diagnosis of ahf according to the opinion of two emergency experts after consulting the data from the clinical examination, cardiac echocardiography, and bnp level. * subject who accept to participate in the research exclusion criteria: * patient who refuse to participate in the study * patient with coronary syndrome with st segment elevation * other causes of dyspnea * impossibility of giving the patient informed information * pregnant woman

Keywords: meessi score acute heart failure
investigating central neurophysiologic correlates of non-motor symptoms of parkinson's disease

Conditions: Parkinson Disease; Autonomic Dysfunction; Depression

Summary: this is a randomized, single-blinded, triple crossover study focused on determining the feasibility of using transcranial magnetic stimulation (tms) for treatment of parkinson's disease related autonomic dysfunction and depression. participants will undergo tms to three brain regions: medial prefrontal cortex (mpfc) (experimental site), dorsolateral prefrontal cortex (dlpfc) (alternative experimental site), or primary sensory cortex (s1) (control site) in a triple crossover design. participants will complete symptom questionnaires, neurologic examination and cognitive assessments, and orthostatic vital signs recording before and after each brain stimulation session.


Eligibility criteria:
inclusion criteria: * men and women between 50 and 90 years of age, without a diagnosis of severe dementia * carry a diagnosis of idiopathic parkinson's disease based on the united kingdom parkinson's disease society brain bank clinical diagnostic criteria * have had symptoms of parkinson's disease for at least 3 years * hospital's study-specific informed consent must be obtained * must have capacity to provide informed consent in english * for female participants, confirmation that a menstrual period has not occurred in over 12 months, or that an effective form of contraception will be used during the study exclusion criteria: * inability to provide informed consent. * severe dementia * history of epilepsy or brain surgery * severe tremor or dyskinesia that would interfere with eeg as determined by the pi * parkinson's patients with clinically significant medical or neurological conditions which may be an alternative cause of orthostatic hypotension, such as neuropathy, renal failure, heart failure, cardiac arrhythmias, severe diabetes, or spinal cord injuries * the investigators will exclude patients who are treated with medications which can significantly lower blood pressure or heart rate, such as antihypertensive medications, diuretics, and alpha-blocking medications * presence of other known central nervous system disease that may interfere with performance or interpretation of eeg or tms * presence of any implanted metal devices including, but not limited to, pacemakers, deep brain stimulators, vagal nerve stimulators, bladder stimulators, or cochlear implants.
study to assess the efficacy, safety and tolerability of lcq908 in nafld patients

Conditions: Non-alcoholic Fatty Liver Disease (NAFLD)

Summary: the purpose of this study was to determine whether lcq908 effectively lowers liver fat, as assessed by mri and to assess its safety and tolerability profile in subjects with non-alcoholic fatty liver disease (nafld).


Eligibility criteria:
inclusion criteria: * history of liver steatosis during the preceding 24 months * history of fasting tgs \> 200 mg/dl (confirmed at screening). * liver fat ≥ 10% as determined by the central mri laboratory. * subjects on the following medications can be included if these medications are medically necessary, cannot be stopped and the investigator feels their dose will remain stable for the duration of the double-blind treatment period: 1. stable dose of anti-diabetic medications (metformin and/or sulfonylureas) for at least 8 weeks prior to screening. 2. stable doses of beta-blockers and thiazide diuretics for at least 8 weeks prior to screening. 3. stable doses of fibrates, statins, niacin, ezetimibe for at least 8 weeks prior to screening. 4. stable dose of vitamin e in patients taking \>200 iu/day for at least 6 months prior to screening. exclusion criteria: * treatment with omega-3-acid ethyl esters or omega-3-polyunsaturated fatty acid (pufa)-containing supplements \> 200 mg per day within 8 weeks of screening. * treatment with antiretrovirals, tamoxifen, methotrexate, cyclophosphamide, isotretinoin, bile acid binding resins or pharmacologic doses of oral glucocorticoids (≥10 mg of prednisone per day or equivalent) within 8 weeks of screening. * alt or ast \> 250 iu/l at the time of screening. * history/current evidence of heavy alcohol use or alcoholism (\> 21 drinks per week in men and \> 14 drinks per week in women) over a 2-year period prior to screening. * presence of chronic liver disease, such as chronic hepatitis b and/or c, alcoholic liver disease, hemochromatosis, wilson's disease, known cirrhosis. * platelet count \<150,000 at screening. * bmi \>45 kg/m2. other protocol defined inclusion/exclusion criteria may apply

Keywords: multi-center, randomized, double-blind, nafld, elevated triglycerides
quantification, analysis and simulation of facial mimics movements

Conditions: Mimic Facial Muscles

Summary: the simovi project is a collaboration between our department of maxillofacial surgery (chu amiens) and the biomechanical bioengineer research department and roberval labs (technological university of compiègne). the question raised is the extent to which a facial mimic can be evaluated objectively. in today's clinical practice, the investigators use grading systems based on muscular scale or testing, in order to evaluate a facial muscular disorder. this assessment remains subjective because the investigators are deducing from surfacing cutaneous deformations the movement quality of the solicited muscle. this qualitative approach is therefore an approximate approach and deserves to be better thought to plan a surgical treatment which involves mimic facial muscle (as rehabilitation of facial palsy, cleft palate for example), to monitor the results, and to follow the recovery and progress in physiotherapy care. the aim of this study is to correlate external soft tissue movement (essentially cutaneous) during facial mimic with internal movement (essentially facial mimic muscle) using qualitative and quantitative indicators, and to perform a biomechanical model of selected mimic face's movement using the precedent data.


Eligibility criteria:
inclusion criteria: * caucasian subject * ability to provide informed consent exclusion criteria: * facial pathology * facial trauma * pregnant or breastfeeding. * contraindications to mri

Keywords: facial mimic muscle mri segmentation three dimensional assessment motion capture movement analysis digital image correlation
coronary flow reserve in patients with bio-active stent or everolimus-eluting stent implanted in acute coronary syndrome

Conditions: Acute Coronary Syndrome

Summary: the aim of the trial is to assess coronary artery reactivity using adenosine-induced coronary flow reserve (cfr) by transthoracic echocardiography in patients with bio-active stent (bas) and everolimus-eluting stent (ees) distal to the original culprit lesion at 6-8 months.

objective: the aim of the trial is to assess coronary artery reactivity using adenosine-induced coronary flow reserve (cfr) by transthoracic echocardiography in patients with bio-active stent (bas) and everolimus-eluting stent (ees) distal to the original culprit lesion at 6-8 months. design: base-cfr is a substudy of the larger randomized multicenter base-acs trial comparing bio-active titan stent to everolimus-eluting stent in patients with acute coronary syndrome. cfr assessment will be performed at 6-8 months after stent implantation at the same time with oct assessment. in-stent restenosis will be ruled out using oct. primary endpoint: cfr at 6-8 months after stent implantation. secondary endpoint: coronary flow velocity at baseline and during adenosine-induced hyperemia 6-8 months after stent implantation.. association of cfr to unendotheliazed stent struts and stent malapposition. enrollment: 40 patients (20 receiving bas and 20 receiving ees). clinical site: satakunta central hospital, finland turku university hospital, finland

Eligibility criteria:
inclusion criteria: * the patient is enrolled to the base-acs trial. treated culprit lesion is in the proximal or middle lad * patient or the patient's legal representative has been informed of the nature of the study and has provided written informed consent as approved by the institutional ethics committee of the respective clinical site exclusion criteria: * diabetes mellitus * treated stent position other than lad proximal or middle. * ef\<30% * bifurcation lesions * renal impairment (creatinine \>120 mmol/l) * no suitable anatomy for oct scan or cfr measurement

Keywords: acute coronary syndrome coronary flow reserve oct healing drug eluting stent
real world study of the clinical profile and treatment outcomes of advanced therapies for ulcerative colitis in portugal

Conditions: Ulcerative Colitis

Summary: this study aims to characterize the portuguese population of patients with moderate-to-severe uc receiving advanced therapies, by describing clinical and sociodemographic characteristics, and remission outcomes . the clinical, biochemical, endoscopic, and histological outcomes will also be described, as well as frequency of selected eim, comorbidities and the uptake of preventive care measures and hospitalizations .


Eligibility criteria:
inclusion criteria: * aged at least 18 years old * diagnosed with ulcerative colitis, confirmed by a gastroenterologist * treated with anti-tnf or anti-integrin or jak inhibitors drugs for at least 16 weeks * followed at one of the participating centers when initiating and during the current treatment * signed informed consent exclusion criteria: * treated with anti-tnf or anti-integrin or jak inhibitors drugs at induction phase * enrolled in randomized clinical trials or other experimental studies in the last 12 months prior to initiation of advanced therapy
association between ora and residual refractive astigmatism after smile

Conditions: Refractive Errors; Astigmatism

Summary: the aim of our study is to analysis and compare the relationship between ora and postoperative astigmatism in low astigmatism (less than 1d) and moderate to high (1d to 3d) astigmatism patients after smile (small incision lenticule extraction) refractive surgery.


Eligibility criteria:
inclusion criteria: * corrected distance visual acuity of both eyes reaches 0.1 logarithm of the minimum angle of resolution (logmar) * stable refractive errors of myopia and astigmatism who received smile refractive surgery of both eyes exclusion criteria: * cataract * corneal opacities or irregularities * dry eye (schirmer's test i ≤ 5mm) * amblyopia * coexisting ocular pathologies * glaucoma * non-dilating pupil * history of intraocular surgery, laser therapy, or retinopathy * optic nerve or macular diseases * estimated postoperative cornea residual stromal thickness less than 250 μm * pregnancy or under lactation * uncontrolled diabetic mellitus or systemic immune disease _refusal or unable to maintain follow-up
the cohort study of early esophageal cancer or precancerous lesions treated with endoscopic resection

Conditions: Early Esophageal Cancer or Precancerous Lesions Treated With Endoscopic Resection

Summary: endoscopic submucosal dissection (esd) is currently the main method of treatment of early esophageal cancer and precancerous lesions. therefore, the investigators are looking forward to conduct a cohort study on early esophageal cancer patients undergoing endoscopic treatment collected from zhongshan hospital, fudan university, comparing the who standard with japanese standard of endoscopic therapy diagnosis. in addition，the investigators will collect patients' detailed informations and analyze the risk factors for metastasis and recurrence of early esophageal cancer.


Eligibility criteria:
inclusion criteria: 1. older than 15-year-old 2. undergoing endoscopic submucosal dissection (esd) in zhongshan hospital exclusion criteria: preoperative patients with recurrence and lost to follow-up of patients within 1 year
comparison of efficacy of denosumab with eldecalcitol or native vitamin d in postmenopausal women with osteoporosis.

Conditions: Osteoporosis in Postmenopausal Women

Summary: primary objective: to compare the bone mineral density (bmd) change under the treatment of denosumab with eldecalcitol or native vitamin d in postmenopausal women with osteoporosis on bone mineral density. secondary objective: to compare the efficacy of denosumab with eldecalcitol or native vitamin d treatment in postmenopausal women with osteoporosis on bone turnover markers, serum pth, serum calcium, serum phosphorus, muscle mass, muscle strength, body balance ability, and quality of life.


Eligibility criteria:
inclusion criteria: * 1.postmenopausal patients with osteoporosis, measured by dual energy x-ray absorptiometry (dxa), the t value of lumbar spine, femoral neck or total hip bmd is ≤-2.5. * 2.voluntarily participate in this study and sign the informed consent. exclusion criteria: * 1.suffering from hyperthyroidism, cushing's syndrome, hypogonadism, poorly controlled diabetes mellitus (glycated hemoglobin \[hba1c\>7.5%\]), or other diseases that may lead to secondary osteoporosis. * 2.patients who have received denosumab therapy before screening: received oral bisphosphonate treatment more than 3 years or received bisphosphonate treatment within 6 months before screening, glucocorticoids, calcitonin, vitamin k, active vitamin d, gonadotropin-releasing hormone agonists, isotopes flavonoids, selective estrogen receptor modulators, or hormone replacement therapy. * 3.patients with urolithiasis revealed by b-ultrasound at screening. * 4.corrected serum calcium value at screening exceeds 2.6mmol/l (10.4mg/dl) or serum calcium value is lower than 2.12mmol/l(8 mg/dl) or hypercalciuria (\> 0.4 mg/dl gf), or chronic kidney disease (egfr \< 30 ml/min/1.73 m2). * 5.patients with malignant tumors or patients with a history of malignant tumors within the previous 3 years. * 6.patients judged by investigators to be unsuitable as subjects.
the role of the living environment in the social inequalities in the physical activities of pregnant women residing in the eurometropole of strasbourg

Conditions: Physical Activity of Pregant Women

Summary: excessive weight gain during pregnancy can promote subsequent obesity or increase pre-existing maternal obesity, lead to complications during pregnancy, such as gestational diabetes, hypertension and pre-pregnancy eclampsia, which affect fetal growth. what are the determinants of excessive weight gain? the first determinant of excessive weight gain is related to healthy living place and physical activity, noted as "pa". many meta-analyses have demonstrated the role of pa in gestational weight gain. the main objective is to study the role of the living environment in the pa practice of pregnant women and to identify the socio-environmental construction contributing to the disparities in the practice of pa in women during their pregnancy. this thesis is based on an innovative approach in france, combining both epidemiology and geography approaches to meet priority research objectives in a public health context. with regard to the general issue "what are the contextual determinants of pregnant women's pa practice beyond their individual characteristics that could explain the disparities in practice according to their socio-economic position?" this question underlies the following assumptions: i) in addition to their individual characteristics, women with low pa and who have reduced pa during pregnancy reside in a more socio-economically deprived neighborhood. ii)beyond the socio-economic dimension, the physical characteristic of the residential place influences the level of pa practice of pregnant women. iii) the combination of the socio-economic, physical and psychosocial environment contributes to reducing the level of pa among pregnant women. iv) pregnant women with an unfavourable living environment and low pa have adverse pregnancy outcomes.


Eligibility criteria:
inclusion criteria: * pregnant women living in the strasbourg eurometropolis * women performing ultrasound follow-up and giving birth in hus * understanding of the french language * patient who has expressed no opposition to the research and/or has signed a consent form in case of collection creation exclusion criteria: * refusal to participate in study * minor women * unable to provide informed information (subject in an emergency, difficulty understanding the subject, etc.) * subject under protection of justice * subject under guardianship or curatorship * obstetric pathologies against-indicating the practice of ap

Keywords: physical activity level neighborhood, social inequalities living environment, gestational weight gain